Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

April 30, 2026

Conditions

Triple Negative Breast CancerNeoadjuvant ImmunotherapySensitivity

Interventions

DRUG

PD-1 inhibitor

PD-1 inhibitor combined with neoadjuvant chemotherapy

All Listed Sponsors

collaborator

Chinese PLA General Hospital

OTHER

lead

Shandong University

OTHER